Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
|Slideshows|September 21, 2018
Putting the Breaks on Low Testosterone and Fractures in Men
Author(s)Gregory M. Weiss, MD
Low serum estradiol found to have a causal effect on bone mineral density and fracture risk in men vs low testosterone, according to a new study.
Advertisement
Reference: Nethander M, Vandenput L, Eriksson AL, et al. Evidence of a causal effect of estradiol on fracture risk in men. J Clin Endocrinol Metab. 2018.
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
4
DAPA-TRIO-HF: Dapagliflozin Improves HF Outcomes Regardless of Healthcare Setting
5